PMID- 36328894
OWN - NLM
STAT- MEDLINE
DCOM- 20230206
LR  - 20230206
IS  - 1499-3872 (Print)
VI  - 22
IP  - 1
DP  - 2023 Feb
TI  - A mixed blessing for liver transplantation patients - Rapamycin.
PG  - 14-21
LID - S1499-3872(22)00240-5 [pii]
LID - 10.1016/j.hbpd.2022.10.004 [doi]
AB  - BACKGROUND: Liver transplantation (LT) is an effective treatment option for 
      end-stage liver disease. Mammalian target of rapamycin (mTOR) inhibitors, such as 
      rapamycin, are widely used post LT. DATA SOURCES: In this review, we focused on 
      the anti-cancer activities and metabolic side effects of rapamycin after LT. The 
      literature available on PubMed for the period of January 1999-September 2022 was 
      reviewed. The key words were rapamycin, sirolimus, liver transplantation, 
      hepatocellular carcinoma, diabetes, and lipid metabolism disorder. RESULTS: 
      Rapamycin has shown excellent effects and is safer than other immunosuppressive 
      regimens. It has exhibited excellent anti-cancer activity and has the potential 
      in preventing hepatocellular carcinoma (HCC) recurrence post LT. Rapamycin is 
      closely related to two long-term complications after LT, diabetes and lipid 
      metabolism disorders. CONCLUSIONS: Rapamycin prevents HCC recurrence post LT in 
      some patients, but it also induces metabolic disorders. Reasonable use of 
      rapamycin benefits the liver recipients.
CI  - Copyright (c) 2022 First Affiliated Hospital, Zhejiang University School of 
      Medicine in China. Published by Elsevier B.V. All rights reserved.
FAU - Fan, Guang-Han
AU  - Fan GH
AD  - Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First 
      People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, 
      China; Zhejiang University School of Medicine, Hangzhou 310058, China; Key 
      Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, 
      Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang University, 
      Hangzhou 310003, China.
FAU - Zhang, Chen-Zhi
AU  - Zhang CZ
AD  - State Key Laboratory of Oncology in South China, Collaborative Innovation Center 
      for Cancer Medicine, Sun Yat-sen University Cancer, Guangzhou 510060, China.
FAU - Gao, Feng-Qiang
AU  - Gao FQ
AD  - Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First 
      People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, 
      China; Zhejiang University School of Medicine, Hangzhou 310058, China; Key 
      Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, 
      Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang University, 
      Hangzhou 310003, China.
FAU - Wei, Xu-Yong
AU  - Wei XY
AD  - Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First 
      People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, 
      China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang 
      Province, Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang 
      University, Hangzhou 310003, China; Westlake Laboratory of Life Sciences and 
      Biomedicine, Hangzhou 310024, China.
FAU - Ling, Sun-Bin
AU  - Ling SB
AD  - Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First 
      People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, 
      China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang 
      Province, Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang 
      University, Hangzhou 310003, China.
FAU - Wang, Kai
AU  - Wang K
AD  - Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First 
      People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, 
      China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang 
      Province, Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang 
      University, Hangzhou 310003, China; Westlake Laboratory of Life Sciences and 
      Biomedicine, Hangzhou 310024, China.
FAU - Wang, Jian-Guo
AU  - Wang JG
AD  - Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First 
      People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, 
      China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang 
      Province, Hangzhou 310006, China; Institute of Organ Transplantation, Zhejiang 
      University, Hangzhou 310003, China.
FAU - Zheng, Shu-Sen
AU  - Zheng SS
AD  - Institute of Organ Transplantation, Zhejiang University, Hangzhou 310003, China; 
      Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; 
      Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, 
      Hangzhou 310000, China; NHC Key Laboratory of Combined Multi-Organ 
      Transplantation, Hangzhou 310003, China.
FAU - Nikfarjam, Mehrdad
AU  - Nikfarjam M
AD  - Department of Surgery, University of Melbourne, Austin Health, Heidelberg, VIC 
      3084, Australia.
FAU - Xu, Xiao
AU  - Xu X
AD  - Zhejiang University School of Medicine, Hangzhou 310058, China; Key Laboratory of 
      Integrated Oncology and Intelligent Medicine of Zhejiang Province, Hangzhou 
      310006, China; Institute of Organ Transplantation, Zhejiang University, Hangzhou 
      310003, China; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 
      310024, China. Electronic address: zjxu@zju.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20221020
PL  - Singapore
TA  - Hepatobiliary Pancreat Dis Int
JT  - Hepatobiliary & pancreatic diseases international : HBPD INT
JID - 101151457
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Humans
MH  - Sirolimus/adverse effects
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - *Liver Transplantation/adverse effects
MH  - *Liver Neoplasms/drug therapy
MH  - Neoplasm Recurrence, Local/drug therapy
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Liver transplantation
OT  - Metabolic disease
OT  - Rapamycin
OT  - Tumor recurrence
EDAT- 2022/11/04 06:00
MHDA- 2023/02/07 06:00
CRDT- 2022/11/03 23:06
PHST- 2022/08/08 00:00 [received]
PHST- 2022/10/14 00:00 [accepted]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2023/02/07 06:00 [medline]
PHST- 2022/11/03 23:06 [entrez]
AID - S1499-3872(22)00240-5 [pii]
AID - 10.1016/j.hbpd.2022.10.004 [doi]
PST - ppublish
SO  - Hepatobiliary Pancreat Dis Int. 2023 Feb;22(1):14-21. doi: 
      10.1016/j.hbpd.2022.10.004. Epub 2022 Oct 20.